Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 109/L?
- Author
- ReachMD
- Published
- Fri 19 Jul 2024
- Episode Link
- http://reachmd.com/programs/cme/case-discussion-what-jak-inhibitor-should-i-use-in-a-transfusion-dependent-patient-with-mf-with-platelets-50-109l/26512/
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-discussion-what-jak-inhibitor-should-i-use-in-a-transfusion-dependent-patient-with-mf-with-platelets-50-109l/26512/
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-discussion-what-jak-inhibitor-should-i-use-in-a-transfusion-dependent-patient-with-mf-with-platelets-50-109l/26512/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
